A New Chapter Begins at CQDM
Montreal, June 11, 2025 — Last night, CQDM paid a heartfelt and grateful tribute to its outgoing President and CEO, Diane Gosselin, co-founder of the organization, as she prepares to retire. Held in the presence of our committee members and many key players from the life sciences ecosystem, the event was an opportunity to celebrate a career marked by exceptional contributions to biopharmaceutical research and innovation in Quebec and across Canada.
For the occasion, we present an exclusive video featuring a conversation between Diane Gosselin and Véronique Dugas, Ph.D., MBA, who is stepping into the role of President and CEO. Together, they reflect on the organization’s major milestones and share their vision for the future of collaborative health innovation.
A Decade of Tangible Impact
Under Diane Gosselin’s leadership, CQDM established itself as a unique catalyst at the intersection of academic research, the pharmaceutical industry, and innovative SMEs. Key accomplishments include:
- 152 projects funded, representing $375M in R&D investments
- Over $222M in co-funding from public and private partners
- Support provided to approximately 120 companies
- Launch of major initiatives such as FACS, CATALIS, and AReNA
CQDM has driven the development of cutting-edge research platforms, the creation of spin-off companies from academic discoveries, and provided targeted support to entrepreneurial innovation.
A Future-Focused Transition
As Véronique Dugas assumes leadership of the organization, she inherits a rich and dynamic ecosystem, well-positioned to take on new challenges. Her appointment reflects a strong sense of continuity in CQDM’s mission: to foster collaboration that accelerates the development of innovative solutions for the benefit of patients.
🎥 Watch the full video of this inspiring transition and hear from two visionary leaders who have shaped—and will continue to shape—the future of CQDM.
